Suboxone is not FDA-approved for treating alcohol use disorder. It is approved only for opioid dependence. However, early research suggests its active ingredient, buprenorphine, may reduce alcohol consumption through its effects on the brain’s opioid system, and some clinicians have observed decreased drinking in patients taking the medication for opioid problems.
What Suboxone Is Approved For
Suboxone contains two ingredients: buprenorphine, a partial opioid activator, and naloxone, an opioid blocker. The FDA approved it specifically for treating opioid dependence as part of a broader plan that includes counseling and psychosocial support. The label makes no mention of alcohol use disorder as a treatment target.
Three other medications do carry FDA approval for alcohol use disorder: naltrexone, acamprosate, and disulfiram. Each works through a different mechanism. Naltrexone blocks the pleasurable effects of alcohol, acamprosate helps stabilize brain chemistry after someone stops drinking, and disulfiram causes unpleasant physical reactions if you drink while taking it. These remain the standard, evidence-based options for alcohol problems.
Why Researchers Think It Might Help
Buprenorphine interacts with several types of opioid receptors in the brain, and some of those receptors play a role in alcohol cravings. It partially activates the mu-opioid receptor, blocks the kappa-opioid receptor, and activates a receptor called nociceptin/orphanin FQ-NOP. Each of these actions could theoretically influence the reward and stress pathways involved in alcohol use.
The kappa receptor connection is particularly interesting. Signaling through kappa receptors contributes to the low mood and heightened stress sensitivity that often drive people back to drinking. By blocking those receptors, buprenorphine may ease the emotional distress that fuels relapse. Researchers have also noted that buprenorphine’s activation of the NOP receptor system appears to directly reduce alcohol intake in animal studies. In one experiment using rats genetically bred to prefer alcohol, buprenorphine reduced voluntary drinking across a range of doses, with the strongest suppression occurring at higher doses.
Clinicians have made similar observations in practice. Researchers behind the animal study noted they had seen “suppression of alcohol drinking by buprenorphine was most pronounced at high doses of the drug (16 to 32 mg daily)” in clinical settings, which motivated the laboratory work.
What Clinical Trials Show
The most relevant human data comes from a secondary analysis of a large randomized trial called CTN X:BOT, which originally compared extended-release naltrexone to buprenorphine-naloxone (the Suboxone combination) for opioid use disorder. Researchers went back and looked at what happened to participants’ drinking during the six-month trial.
Both groups reduced their alcohol consumption from baseline, with small to medium effect sizes. The key finding: there was no significant difference between the two medications. Researchers had hypothesized that naltrexone, which is actually approved for alcohol problems, would outperform buprenorphine-naloxone on drinking outcomes. It didn’t. Both medications were associated with similar reductions in the frequency of any drinking and heavy drinking, and similar timelines to first drink and first heavy drinking day.
For participants who entered the trial with an alcohol use disorder diagnosis or recent heavy drinking, there was additional evidence that drinking was further reduced by treatment, but again, neither medication proved superior to the other. This suggests buprenorphine-naloxone may have a real, if modest, effect on alcohol consumption, though it’s worth noting these patients were being treated primarily for opioid problems, not alcohol use disorder alone.
The Danger of Drinking on Suboxone
Even if buprenorphine shows some promise for reducing alcohol cravings, combining Suboxone with alcohol is genuinely dangerous. Both substances slow the central nervous system. Together, they amplify each other’s sedating effects in ways that can become life-threatening.
Alcohol increases the brain’s production of an inhibitory chemical called GABA. Too much of this chemical can lower your heart rate, breathing rate, and body temperature to critical levels. Add buprenorphine’s own respiratory effects, and the combination can lead to:
- Severely slowed or stopped breathing
- Extreme drowsiness or loss of consciousness
- Coma
- Impaired speech and coordination
The FDA label for Suboxone specifically warns about this. Many post-marketing reports of coma and death involved concomitant use of buprenorphine with other central nervous system depressants, including alcohol. Patients starting Suboxone are supposed to be educated about this risk as a routine part of treatment. If you’re taking Suboxone for opioid dependence and also drinking, the interaction is a serious medical concern, not a therapeutic strategy.
Co-Occurring Opioid and Alcohol Problems
Where Suboxone most plausibly helps with alcohol use is in people who have both opioid and alcohol problems at the same time. This is common. Patients receiving opioid maintenance treatments frequently misuse other substances, including alcohol, benzodiazepines, and cannabis.
For someone whose primary diagnosis is opioid use disorder but who also drinks heavily, Suboxone treatment may reduce both behaviors simultaneously. The X:BOT trial data supports this possibility, showing that drinking declined alongside opioid use during treatment. In this context, a prescriber might reasonably choose Suboxone knowing it could address both issues, even though the alcohol benefit is not the primary indication.
For someone whose only problem is alcohol, there is currently no strong clinical evidence to support prescribing Suboxone. No large, well-designed trial has tested buprenorphine specifically as a treatment for alcohol use disorder in people without opioid problems. The animal research and clinical observations are suggestive, but the approved medications for alcohol use disorder, particularly naltrexone, have a much stronger evidence base for that specific purpose.
How It Compares to Naltrexone
Naltrexone is the closest comparison because both drugs act on opioid receptors, but they work in opposite directions. Naltrexone fully blocks the mu-opioid receptor, which means it prevents alcohol from producing its rewarding buzz. Buprenorphine partially activates that same receptor while blocking the kappa receptor. Both approaches reduce drinking, but they do so through different pathways.
In the head-to-head comparison from the X:BOT trial, neither came out ahead on drinking outcomes over six months. That result is intriguing but limited, because the study wasn’t designed to test either drug as an alcohol treatment. Participants weren’t selected for alcohol problems, and alcohol reduction wasn’t the primary endpoint. Until a trial specifically enrolls people with alcohol use disorder and randomizes them to buprenorphine versus naltrexone, the comparison remains incomplete.
For now, naltrexone has decades of clinical trial evidence supporting its use for alcohol use disorder, is FDA-approved for that purpose, and comes in both daily pill and monthly injection forms. Buprenorphine has biological plausibility, encouraging secondary analyses, and clinical anecdotes, but not the kind of evidence that changes prescribing guidelines.